Internal version (manual rotation) is attempted only in:

A. assess the fetal heart rate (FHR) pattern: The sudden release of amniotic fluid can cause the umbilical cord to wash down ahead of the fetal part, leading to prolapse. Monitoring the heart rate immediately detects any sudden bradycardia or variable decelerations caused by cord occlusion. This is the highest priority for fetal safety.

B. perform a vaginal examination: A digital exam can confirm a cord prolapse or check cervical progress, but it is not the first action required. The fetal heart rate provides immediate data on fetal status and the urgency of the situation. Physical assessment follows the electronic confirmation of fetal stability or distress.

C. inspect the characteristics of the fluid: Checking for meconium staining or foul odor provides information about fetal maturity, stress, or infection risk. While important for long-term planning, these findings do not present the immediate life-threat that a cord prolapse does. Fluid inspection is secondary to heart rate assessment.

D. assess maternal temperature: Monitoring for pyrexia is essential to screen for chorioamnionitis following the rupture of protective membranes. However, infection typically takes hours to develop and manifest clinically. The immediate risk of mechanical cord compression requires a more urgent response via heart rate monitoring.

A. Fentanyl: This is a potent synthetic opioid agonist used for analgesia during labor or surgery. Administering another opioid to a newborn already experiencing respiratory depression from Stadol would exacerbate the condition and worsen neonatal outcomes. It does not possess any antagonist properties to reverse sedative effects.

B. Narcan: Naloxone is a pure opioid antagonist that competes for mu, kappa, and delta opiate receptor sites in the central nervous system. It rapidly reverses the respiratory depression and sedation caused by mixed agonist-antagonist drugs like butorphanol. It is the standard emergency treatment for neonatal opioid exposure.

C. Nembutal: Pentobarbital is a short-acting barbiturate used for sedation and the management of seizures or increased intracranial pressure. It has no role in reversing opioid-induced depression and would further depress the neonatal central nervous system and respiratory drive. It is contraindicated in this clinical scenario.

D. Nubain: Nalbuphine is a mixed opioid agonist-antagonist similar in pharmacological profile to butorphanol (Stadol). Using this medication would potentially increase the total opioid load and worsen the postnatal effects on the newborn. It is used for maternal pain relief, not for neonatal resuscitation or reversal.